Compare Incyte Corporation (INCY) vs Marathon Digital Holdings Inc (MARA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Marathon Digital Holdings Inc — how do they compare? Incyte Corporation trades at $115.71 (market cap $23.11B), while Marathon Digital Holdings Inc trades at $11.99 (market cap $4.45B). The key difference: Incyte Corporation is far larger — about 5.2× Marathon Digital Holdings Inc's market cap, and Incyte Corporation is trading nearer its 52-week high, Marathon Digital Holdings Inc nearer its low. Which is the better fit depends on your goals.
| INCY | MARA | |
|---|---|---|
Market Cap | $23.11B | $4.45B |
Sector | Health | Technology |
52-Week High | $118.52 | $22.84 |
52-Week Low | $67.38 | $6.73 |
Enterprise Value | $19.13B | $6.40B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INCY trades at $115.66, down 1.36% on the day, with a bullish technical signal from moving averages and strong fundamental performance including a 25.02% net income margin for 2025. Recent positive news includes regulatory approvals for Opzelura in Europe and the acquisition of Vega Therapeutics, expanding its hematology portfolio. Revenue grew to $5.14 billion in 2025, with earnings beating expectations in two of the last three quarters.
The outlook remains positive given robust profitability, pipeline advancements, and a majority analyst buy rating, though risks include competitive pressures and reliance on key drug performance. The stock's current price is slightly above the consensus target of $112.78, suggesting near-term consolidation potential amid longer-term growth catalysts.
Marathon Digital Holdings (MARA) trades at $11.67, up 9.17% today, amid a strategic pivot from Bitcoin mining to AI infrastructure. Despite recent earnings misses and negative profitability metrics, the stock shows technical support near $10-11 levels. The company's acquisition of a 1,200-acre Texas site with 2 GW power capacity represents a significant expansion opportunity, though cash flow remains negative from operations.
MARA presents a high-risk opportunity with Wall Street analysts maintaining a 50% buy rating and $16.90 consensus target. The AI pivot could drive long-term growth, but investors face substantial execution risks amid persistent losses and negative cash flow. Near-term performance depends on successful business transformation and improved profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Marathon Digital Holdings Inc
Marathon Digital Holdings, Inc. is one of the largest publicly traded Bitcoin mining companies in North America. The company focuses on building and operating large-scale, cost-efficient Bitcoin mining facilities. Marathon's strategy centers on increasing its mining hash rate and using sustainable energy sources to expand its Bitcoin production. The company's performance is closely tied to the price of Bitcoin and the overall health of the digital asset mining industry.
Read more on MARA →
